NCI funds catalyze integrative cancer biology program
Todd Golub, M.D.Photo courtesy of L. Barry Hetherington
Biomedical research has increasingly required the integration of experimental and computational approaches. The area of cancer biology is no different. Now the National Cancer Institute (NCI) has awarded $12.6 million over five years to a group of investigators at the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute (DFCI) to encourage the emergence of integrative cancer biology as a distinct field of research.
The grant went to principal investigator Todd Golub, M.D., to establish an Integrative Cancer Biology (ICB) program at the Broad Institute and DFCI.
This grant also includes Broad investigators Eric Lander, Steven Carr, Jill Mesirov, and Pablo Tamayo; Broad/DFCI investigators William Hahn and Matthew Meyerson; DFCI investigators Gary Gilliland, James Griffin and Thomas Roberts; and Broad/Harvard Medical School investigator Ed Harlow.
The researchers have a single focus, which entails determining the molecular signatures of each kinase (a class of proteins) in the human genome.
Kinases play a central role in the pathogenesis for most, if not all cancers, and represent excellent therapeutic targets, said Golub, director of Broad's Cancer Program.
The researchers will use these molecular signatures to measure gene expression results, and then develop computational models predictive of kinase activation and its essentiality in cancer cells, said the scientists.
In addition to its scientific goal, the program will focus on community outreach and the training of biologists, computationalists, and undergraduate students about the interface of computation and cancer biology.
"This program will represent a vehicle to unite a great team of scientists interested in working together toward a single goal. It will also serve to further our efforts to work at the interface of cancer biology and computational biology," said Golub, who is also a Charles A. Dana Investigator at DFCI.
Eight other centers were established through the ICB program at Duke University, Lawrence Berkeley National Laboratory, Massachusetts General Hospital, Massachusetts Institute of Technology, Ohio State University, Stanford University School of Medicine, University Hospital of Cleveland, University School of Medicine and Vanderbilt University Medical Center.
The ICB program is a unique initiative designed to gain new insights into the development and progression of cancer through a systems-wide approach. Research conducted through the ICB program could ultimately lead to the development of improved cancer interventions.
"The key aspect that sets the ICB program effort apart from others is the focus on building predictive cancer models, and not just analyzing data," said Daniel Gallahan, Ph.D., associate director, Division of Cancer Biology, NCI.